Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a trailblazer in the development of Antibody Radiation Conjugates (ARCs) and targeted radiotherapy treatments, is at the forefront of oncology innovation with its latest venture into improving CAR T-cell therapy. The company announced a partnership with the University of Texas Southwestern Medical Center (UT Southwestern) to initiate a clinical trial focused on their pioneering product, Iomab-ACT, as a conditioning agent before CAR T-cell therapy. This move not only underscores Actinium’s commitment to enhancing cancer treatment but also marks a significant stride towards reducing the toxicities associated with current conditioning regimens.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50 th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 – 17, 2024, in Glasgow, Scotland . Iomab-B is a targeted radiotherapy conditioning agent comprised of an anti-CD45 monoclonal antibody and Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving Iomab-B and a bone marrow transplant (BMT) to those of patients receiving physician’s choice of care in the control arm. In total, 24% of patients (37/153) in the SIERRA trial had a TP53 mutation, which is associated with poor outcomes, and 27 of the TP53 positive patients received Iomab-B. Iomab-B met the primary endpoint of durable Complete Remission (dCR) in the SIERRA trial with high-statistical significance (p<0.0001) and 100% of patients receiving a therapeutic dose of Iomab-B achieved BMT access and engagement
Iomab-ACT: A Leap Forward
Iomab-ACT is designed to replace the chemotherapy conditioning regimens that are presently used before cell and gene therapies. These traditional regimens are known for their significant toxicities, such as immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), which can limit patient access to CAR-T therapies and result in poorer outcomes. Iomab-ACT aims to provide targeted lymphodepletion with minimal incidences of these major toxicities, potentially increasing patient access to CAR-T therapies and improving their efficacy.
A Pivotal Moment for Actinium
Sandesh Seth, Actinium’s Chairman and CEO, highlights the importance of the Iomab-ACT program, viewing it as a potential game-changer in the practice of cellular therapies. With the CAR-T and gene therapy market expected to nearly double by 2030, reaching approximately 93,000 patients annually in the U.S. alone, Iomab-ACT positions Actinium at the cutting edge of targeted radiotherapy applications.
Collaborative Clinical Trials
Dr. Avinash Desai, Actinium’s Chief Medical Officer, expresses excitement over the collaboration with UT Southwestern for this groundbreaking trial. The study aims to demonstrate Iomab-ACT’s ability to reduce CAR-T related toxicities, such as ICANS and CRS, and to improve overall therapy efficacy. Preliminary results from a phase 1 trial with Memorial Sloan Kettering’s CD19 CAR-T therapy have shown promising outcomes, laying the groundwork for the upcoming study with a commercial CAR-T therapy.
The Future of Cellular Therapy Conditioning
The development of Iomab-ACT is part of Actinium’s broader vision to revolutionize conditioning for cellular and gene therapies. With a rapidly expanding pipeline of CAR-T and gene therapies, the potential patient population for these treatments is expected to grow significantly. Actinium’s continued development of targeted conditioning programs like Iomab-ACT holds the promise of enhancing access and outcomes for patients undergoing these transformative treatments.
Actinium Pharmaceuticals: A Visionary in Oncology
Actinium Pharmaceuticals stands as a leader in developing targeted radiotherapies aimed at improving survival for patients who have exhausted conventional oncology treatments. With advanced pipeline candidates like Iomab-B and Actimab-A showing potential in extending survival outcomes for acute myeloid leukemia, Actinium is poised to make significant contributions to the field of oncology.
For traders and investors, Actinium’s innovative approach to CAR T-cell therapy conditioning represents a compelling investment opportunity. The company’s focus on improving the efficacy and accessibility of CAR-T and gene therapies could position it as a key player in the rapidly growing oncology market. As Actinium continues to advance its pipeline and forge strategic partnerships, its potential for growth and impact in the biopharmaceutical industry remains significant.
Significant Upside Potential
Based on 4 Wall Street analysts offering 12 month price targets for Actinium Pharmaceuticals in the last 3 months. The average price target is $30.50 with a high forecast of $50.00 and a low forecast of $16.00. The average price target represents a 289.53% change from the last price of $7.83.
Stay tuned for updates on this exciting journey, as Actinium Pharmaceuticals continues to redefine the landscape of cancer treatment and cellular therapy.
Sources:
https://www.tipranks.com/stocks/atnm/forecast#google_vignette
https://finance.yahoo.com/news/actinium-announces-clinical-trial-study-111800504.html
On Friday, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) saw a price increase of 0.06 USD (5.45%), reaching 1.16 USD with a trading volume of 26.13M against the previous 22.65M, valuing the company at 2.50B USD. Nikola Corporation (NASDAQ: NKLA) experienced a surge of 0.13 USD (14.40%) to 1.04 USD, with a massive trade volume of 163.84M over the prior 93.28M, bringing its valuation to 1.39B USD. OPKO Health, Inc. (NASDAQ: OPK) climbed by 0.13 USD (12.15%) to 1.2 USD, trading 28.90M shares compared to 15.28M previously, and is now worth 836.39M USD. Bitfarms Ltd. (NASDAQ: BITF) increased by 0.07 USD (3.24%) to 2.23 USD with a volume of 38.33M versus 26.99M, with the market capitalization at 747.56M USD. Lastly, Tellurian Inc. (NYSEAMERICAN: TELL) went up by 0.07 USD (11.40%) to 0.6614 USD, on a volume of 47.17M compared to 38.61M before, totaling a valuation of 517.47M USD.
